Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2009

View Archived Issues

Detailed results of CORD I study of Xiaflex in Dupuytren's contracture released

AP-1 and NF-kappaB inhibitors in early development at Bristol-Myers Squibb

Hovione's TwinCaps inhaler succesful in phase III influenza trial of CS-8958

Galenica acquires Om Pharma

Amarillo Biosciences provides update on phase II interferon alpha trial in influenza and colds

Cell Biosciences to acquire Alpha Innotech

AmorePacific describes TRPV1 antagonists for the treatment of pain

Osiris Therapeutics presents preliminary results for phase III Prochymal trials

S*Bio discloses PI3K and mTOR inhibitors as oncolytics

PDE4 inhibitors and mAChRs antagonists disclosed by GSK for respiratory diseases

Bristol-Myers Squibb presents SERT inhibitors and NK1 antagonists as anxiolytics

Medivation Technologies presents novel compounds for cognitive and psychotic disorders

Phase I/II study to determine safety/efficacy of KP-413 in atopic dermatitis

West Nile virus antibody MGAWN1 to be evaluated in phase II trial

Vivus reports results from two phase III Qnexa studies

M.D. Anderson Cancer Center and Arno Therapeutics to assess DB-67 in MDS in phase II trial

Brivanib alaninate is active as first- and second-line treatment in HCC patients

Prospective study shows tendency of menatetrenone to suppress postoperative HCC recurrence

ABT-869 exhibits promising clinical activity in Child-Pugh Type A HCC patients in phase II trial

ISTA presents preliminary results for T-Pred studies

FDA approves Bepreve for the treatment of ocular itching due to allergies

Salix receives FDA marketing approval for Metozolv ODT

Aeolus commences study of AEOL-10150 as a countermeasure to radiation

Aclidinium bromide improves pulmonary function in phase III trials; MAA filing planned for 2010

ChemGenex submits NDA to FDA for Omapro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...